GITNUX MARKETDATA
Browse Our Category
Medical Conditions Disorders
Latest update:
Postpartum Preeclampsia Statistics
Postpartum preeclampsia is rare but serious, affecting about 3% to 5% of pregnancies globally and showing up with seizures in case series within days to weeks after delivery. Get the practical timing and treatment signals that change outcomes, including WHO advice to check blood pressure no later than 7 to 10 days postpartum, recurrence risk often estimated around 20%, and evidence that remote blood pressure monitoring can cut postpartum readmissions for hypertensive disorders by 25%.
Women Heart Attack Statistics
In the U.S., women make up 53.0% of age adjusted cardiovascular disease deaths and 1 in 5 women who have a heart attack dies, yet they are less likely to get timely, guideline recommended care like reperfusion therapies and aspirin within 24 hours. Women’s symptoms are also more often atypical, including nausea or shortness of breath, which can delay emergency action and shape outcomes, even though cardiac rehab can cut all cause mortality by about 20%.
Hsv1 Statistics
HSV-1 diagnosis can swing from near perfect to misleading, with type-specific gG testing and PCR catching active lesions in 95 to 100 percent while IgM stays unreliable with 30 to 50 percent false positives. You also get the clinical reality checks that matter, including CSF PCR for encephalitis at 98 percent sensitivity and 94 percent specificity and the global snapshot that about 3.7 billion people under 50 carry HSV-1, shaping both testing choices and transmission risk.
Macular Degeneration Statistics
The latest AMD snapshot shows early disease in 10.6% of U.S. adults 40 and older alongside a steep late AMD pipeline, where 5 to 15 year incidence climbs from single digit rates to 3.3% in the Beaver Dam Eye Study and up to 43% advanced risk at 5 years for AREDS high risk patients. You will also see what actually shifts outcomes, from anti VE GF schedules that average every 4 to 8 weeks and boost vision responders in VIEW 1 and VIEW 2 to geographic atrophy therapies that slow lesion growth by 27% to 29%, plus the real-world access and cost pressures that can quietly decide who gets treated on time.
Leukemia Statistics
With an estimated 311,594 leukemia deaths worldwide in 2020, the page sets the stakes high, then pivots to what modern therapy can change, from CML outcomes improved by tyrosine kinase inhibitors to nilotinib and dasatinib trial results that push event free and molecular responses further than imatinib. You will see how survival metrics, response rates, and treatment costs connect across CLL, CML, AML, and ALL so you can understand both progress and ongoing urgency.
Pid Statistics
PID is behind astonishing gains across industries, from 0.5°C room temperature control in 95% of commercial buildings to 200Hz drone attitude stabilization and wafer temperature accuracy of ±0.1°C across 300mm. Then the page pivots from classic wins to real tradeoffs, comparing PID against MPC, fuzzy, adaptive, and neural hybrids where complexity rises 15% but error reduction can jump by 28% or more.
Brain Tumor Statistics
Oligodendroglioma still posts a 74.1% five year relative survival in SEER, but the treatment evidence swings sharply from hazard ratio 0.63 with radiotherapy plus temozolomide to only 4.2 months median progression free survival with bevacizumab versus 3.7 months without, making tumor biology and trial design feel inseparable. If you want what is actually actionable, the page connects molecular markers like IDH1/2 and MGMT promoter methylation with outcomes and translates U.S. surveillance scale through SEER tools and updated survival patterns.
Metastatic Cancer Statistics
Metastatic cancer is still stealing the most time and life, with 5 year relative survival at just 30% for metastatic breast cancer and distant stage responsible for 28% of cancer deaths in the United States. Yet the page also tracks what is changing fast, from actionable biomarker eligibility in 52% of advanced non small cell lung cancer to how therapy adoption, costs, and survival benchmarks diverge sharply by tumor type and treatment line.
Hodgkins Lymphoma Statistics
From 15% NLPHL cases to the immune signals that shape classical Hodgkin lymphoma, this page pulls together current biomarkers like FOXP3 enriched in the tumor microenvironment and EBV positivity, alongside actionable response and survival benchmarks such as 92.1% 5 year overall survival for brentuximab vedotin plus AVD in ECHELON-1. It also pairs treatment efficacy and risk tools with real world access and survivorship stakes, where cost barriers and radiation related second cancer risk can reshape outcomes long after diagnosis.
Graves Disease Statistics
Graves disease is uncommon overall yet disproportionately affects women, with age standardized prevalence reported at 0.34 percent in a large US health system and Graves ophthalmopathy appearing in about 25 percent of patients. This page connects practical markers like TRAb positivity in roughly 90 percent of cases to outcomes that drive long term costs and disability, including the shift from active eye disease to relapse, hypothyroidism after radioiodine, and measurable work and quality of life impacts.
Liver Disease Statistics
With hepatitis C cure rates above 95% and ultrasound surveillance cutting 1 year death risk for HCC by about 37%, the page shows how modern care can sharply change outcomes. It also contrasts that promise with the size of the burden and costs, including U.S. liver transplants around 1,000 living donor procedures in 2020 and projected NAFLD economic impact reaching $26.3 billion globally by 2030.
Sudep Statistics
Sudep strikes most often in adult men and about 80% of cases happen at night, yet the risk swings sharply with practical factors like uncontrolled convulsive seizures and whether someone is watched during sleep. See the page for the latest adult baseline of about 1.2 per 1,000 patient years and the stark contrast in children and high risk groups, plus key autopsy clues and prevention targets that can change outcomes.
Hepatitis Statistics
Chronic hepatitis is still a scale problem but the trajectory is changing fast. From 354 million people living with chronic HBV in 2016 to modern testing and treatment scale ups including 3.6 million people getting HCV testing and 1.3 million starting treatment through 2022 programs, this page connects key global and country snapshots with the gaps that keep transmission going.
Hcc Statistics
For distant stage liver cancer, 5 year relative survival in SEER is just 5.7 percent using 2013 to 2019 data while untreated advanced HCC often has median overall survival under 1 year, setting a stark baseline against modern progress. This page connects those outcomes to what is changing now, from 2020 to 2021 real world treatment patterns and 38 percent lower death risk with atezolizumab plus bevacizumab to 85 percent pooled sensitivity for multiparametric MRI and the persistent gap in chronic HBV and HCV diagnosis and surveillance.
Bone Cancer Survival Statistics
See how bone cancer outcomes swing by stage and timing, from SEER’s 25 percent diagnosed as regional to relapse and survival differences that widen when metastases are present at diagnosis. You will also find race and ethnicity patterns from SEER Explorer plus survival drivers like surgical margins, tumor necrosis, and chemo response, with NCI stage based 5 year estimates for osteosarcoma, chondrosarcoma, and Ewing sarcoma or PNET.
Epilepsy Statistics
About 1 in 10 people who have seizures live with epilepsy, yet care gaps and side effects still shape outcomes from a 40% to 50% 1st seizure recurrence risk to high rates of missed doses and poor adherence. From WHO and IHME disability rankings to US costs and real-world treatment barriers, this page pulls together the most current, concrete measures behind who is affected, what drives disability, and why better epilepsy care matters.
Acute Myeloid Leukemia Statistics
With a US 5 year relative survival rate of about 30% for AML and typical median overall survival for unfit older patients historically only 4 to 10 months, this page highlights why outcomes can diverge so sharply when molecular testing and targeted therapies come into play, including how azacitidine plus venetoclax improves overall survival beyond azacitidine alone. You will also see trial endpoints like CRi and MRD negativity, plus how 18,000 plus AML clinical trials on ClinicalTrials.gov worldwide reflect the push to turn genetics such as FLT3, IDH1 and IDH2 into measurable patient benefit.
Mesothelioma Survival Statistics
See how multimodality decisions change the odds with benchmarks like 23.0 months median overall survival in the MAPS2 surgery inclusive pathway, versus about 12 months for typical real world malignant pleural mesothelioma and 7.7 months for non surgical patients. You will also find survival linked details such as 19 months with EPP plus chemotherapy, platinum chemotherapy plan duration and maintenance timing, and immunotherapy disease control signals like the higher complete or partial response and stable disease rate in CheckMate 743 that help explain why some patients last far beyond the median.
Kleptomania Statistics
Kleptomania is rare, with DSM based estimates putting lifetime prevalence at just 0.1% to 0.3%, yet the DSM 5 pattern of rising tension before the act and relief afterward helps explain why it is often confused with other impulse related behaviors. The page also sets that rarity in context with major comparators and comorbidity data, showing how often related conditions overlap, and what evidence supports treatments like ERP and SSRI based approaches.
Waterborne Diseases Statistics
Waterborne diseases still claim 1.5 million deaths from diarrheal illness each year, and 17% of those deaths are linked to unsafe water, sanitation, and hygiene. This page connects that loss to measurable gaps, like 45% safely managed sanitation coverage and a 39% risk drop from proper drinking water treatment, then follows the trail through major outbreaks, school and household costs, and what it would take to cut inaction.